Show/Hide Menu

Engineering the medicines 
of tomorrow

Learn how MorphoSys approaches drug development.

More Info

Hematological cancers 
affect adults and children alike.

MorphoSys is developing several blood cancer programs.

More Info

Antibody drugs have transformed the way 
inflammatory and autoimmune diseases are treated today.

MorphoSys is exploring new approaches to continue this success.

More Info

Solid tumors can occur in 
several organs of the human body.

MorphoSys and its partners are working on a broad portfolio of new therapies.

More Info

MorphoSys's vision

MorphoSys is committed to developing exceptional new treatments for patients suffering from serious diseases. A leader in the field of therapeutic antibodies today, MorphoSys is driven by the ambition of creating the most valuable pipeline of biopharmaceuticals in the biotechnology industry.

learn more about the company

05/03/2016
Webcast Publication of Q1 2016 Financial results

Full details

Latest
news

21/04/2016
MorphoSys AG : MorphoSys Provides Update on Results From Partner's Phase...
18/04/2016
MorphoSys Licensing Partner GSK Starts Phase 2 Study with GSK3196165 (...
07/04/2016
MorphoSys and Galapagos Initiate Phase 1 Study in Joint Antibody Program...
06/04/2016
MorphoSys Initiates Phase 2 Combination Trial of MOR208 and Lenalidomide...
04/04/2016
Ad hoc: MorphoSys Sues Janssen Biotech and Genmab for Patent Infringement
02/03/2016
MorphoSys AG Reports Results for Fiscal Year 2015
24/02/2016
MorphoSys Announces Share Buy-Back Program
26/01/2016
MorphoSys Announces Clinical Milestone for Start of Bayer's Phase 2 Trial...
07/12/2015
MorphoSys Presents Interim Safety, Pharmacokinetic and Efficacy Data for...
07/12/2015
New Clinical Data on MorphoSys's Blood Cancer Drug Candidate MOR208 in NHL...

Therapeutic pipeline

MorphoSys has established one of the broadest pipelines in the biopharmaceutical industry.
Pipeline

Media and investors

MorphoSys is driven by the ambition to create the most valuable pipeline of biopharmaceuticals in the industry.
Media and investors

Partnering opportunities

Collaborations are a main component of our strategy. We are open to discuss deal structures where we can contribute to the development of novel drugs in a significant way.
Partnering opportunities

Drug development capabilities

MorphoSys is dedicated to become a fully integrated biopharmaceutical company including late stage clinical development and marketing/co-promotion of its own drugs.
Drug development capabilities

Leading antibody technologies

MorphoSys has made HuCAL and its successor technology Ylanthia into reliable sources of therapeutic antibody candidates.
Leading Antibody Technologies

Proprietary program MOR208

When blood formation leads to cancer: the CD19-antibody MOR208 is currently being evaluated in ALL, CLL and NHL.
MOR208

Antibody backgrounder

Antibodies are essential to life. Today, these molecules are used as therapeutic agents for the treatment of severe diseases.
Antibody Backgrounder

Proprietary program MOR209

Together with Emergent BioSolutions, MorphoSys is developing a new way to fight prostate cancer.
MOR209

Partnered program bimagrumab

A new therapeutic approach in musculoskeletal diseases.
Bimagrumab